As the respiratory market continues to grow and evolve, DFE Pharma is proud to announce the capability development at the Closer to the Formulator Centre (C2F) in developing critical inhalation treatments.

Since September 2022, C2F Centre has been pivotal in accelerating the market entry for pharmaceutical products, especially oral solid dosage forms. Effective treatment requirements through DPIs have increased significantly, hence DFE Pharma is expanding its expertise and facilities to address this essential area.

This extension is a concrete step in our commitment to respiratory health and comprises:

• Meeting the Growing Demand: With the continuous surge of respiratory diseases, the company's enhanced capabilities will facilitate the development of innovative DPI products.
• Cutting-Edge Technology and Expertise: Equipped with state-of-the-art technology, our C2F Center now offers specialized DPI product development services, joining the ranks of a select few laboratories worldwide with this capability.

At DFE Pharma, we remain dedicated to driving pharmaceutical innovation and ensuring better health outcomes through advanced inhalation treatments.